RU94042742A - Preparation of genetic engineering gamma-interferon - Google Patents

Preparation of genetic engineering gamma-interferon

Info

Publication number
RU94042742A
RU94042742A RU94042742/14A RU94042742A RU94042742A RU 94042742 A RU94042742 A RU 94042742A RU 94042742/14 A RU94042742/14 A RU 94042742/14A RU 94042742 A RU94042742 A RU 94042742A RU 94042742 A RU94042742 A RU 94042742A
Authority
RU
Russia
Prior art keywords
preparation
amino acid
antiviral activity
interferon
drug
Prior art date
Application number
RU94042742/14A
Other languages
Russian (ru)
Other versions
RU2077336C1 (en
Inventor
А.Н. Сомов
П.А. Черепанов
В.С. Федюкин
В.М. Павлов
Г.Ф. Асташкина
Н.А. Шматченко
Original Assignee
Государственный научно-исследовательский институт прикладной микробиологии
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственный научно-исследовательский институт прикладной микробиологии filed Critical Государственный научно-исследовательский институт прикладной микробиологии
Priority to RU94042742/14A priority Critical patent/RU2077336C1/en
Application granted granted Critical
Publication of RU2077336C1 publication Critical patent/RU2077336C1/en
Publication of RU94042742A publication Critical patent/RU94042742A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FIELD: biotechnology, medicine, pharmacy, veterinary science. SUBSTANCE: invention proposes the preparation based on genetic engineering gamma-interferon (molecular mass is 16.7 kDa) consisting of 144 amino acid residues and exhibiting high purity. Preparation is obtained by microbiological synthesis followed by chromatography purification. Specific antiviral activity of preparation is 2 x 10IU/mg protein (not less), content of the basic substance is 95% (not less) as monomer and 5% (not above) of dimer. Preparation has biologically inert low-molecular polymeric filling agent-stabilizing agent (polyvinylpyrrolidone or dextran) and salt buffer system, pH = 4.5-7.5; preparation can contain also amino acid argentine, histidine or lysine or its physiologically acceptable salt at amount 0.5-3%, and nonionogenic surface-active substance. Dry preparation can be stored for at least one year without inactivation. EFFECT: high antiviral activity, good stability.

Claims (1)

Изобретение относится к биотехнологии, фармации, медицине и ветеринарии и может быть использовано для профилактики и лечения вирусных заболеваний, новообразований и расстройств иммунитета у людей и животных. Предлагается препарат на основе высокоочищенного генно-инженерного гамма-интерферона с молекулярной массой 16,7 кДальтон, состоящего из 144 аминокислотных остатков и полученного микробиологическим синтезом с последующей хроматографической очисткой. Препарат имеет удельную антивирусную активность не менее 2*107 МЕ/мг белка и содержит, по данным ПААГ-ДСН электрофореза, не менее 95% основного вещества в форме мономера, а в димерной форме не более 5%. Препарат имеет в своем составе биологически инертный низкомолекулярный полимерный наполнитель-стабилизатор (поливинилпирролидон либо декстран) и солевую буферную систему с рН 4,5-7,5; в состав препарата также может входить аминокислота аргинин, гистидин или лизин либо ее физиологически приемлемая соль в количестве от 0,5 до 3% и неионогенное поверхностно-активное вещество. Препарат обладает высокой антивирусной активностью и хорошей стабильностью (сухой препарат может храниться без потери активности не менее года).The invention relates to biotechnology, pharmacy, medicine and veterinary medicine and can be used for the prevention and treatment of viral diseases, neoplasms and immune disorders in humans and animals. A preparation based on highly purified genetic engineering gamma-interferon with a molecular weight of 16.7 kDaltons, consisting of 144 amino acid residues and obtained by microbiological synthesis followed by chromatographic purification, is proposed. The drug has a specific antiviral activity of at least 2 * 10 7 IU / mg protein and, according to SDS-SDS electrophoresis, contains at least 95% of the basic substance in the form of a monomer, and in the dimeric form, no more than 5%. The preparation incorporates a biologically inert low molecular weight polymer filler-stabilizer (polyvinylpyrrolidone or dextran) and a salt buffering system with a pH of 4.5-7.5; the composition of the drug may also include the amino acid arginine, histidine or lysine or its physiologically acceptable salt in an amount of from 0.5 to 3% and a nonionic surfactant. The drug has high antiviral activity and good stability (a dry preparation can be stored without loss of activity for at least a year).
RU94042742/14A 1994-12-06 1994-12-06 Genetic-engineering gamma-interferon preparation RU2077336C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94042742/14A RU2077336C1 (en) 1994-12-06 1994-12-06 Genetic-engineering gamma-interferon preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94042742/14A RU2077336C1 (en) 1994-12-06 1994-12-06 Genetic-engineering gamma-interferon preparation

Publications (2)

Publication Number Publication Date
RU2077336C1 RU2077336C1 (en) 1997-04-20
RU94042742A true RU94042742A (en) 1997-06-10

Family

ID=20162865

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94042742/14A RU2077336C1 (en) 1994-12-06 1994-12-06 Genetic-engineering gamma-interferon preparation

Country Status (1)

Country Link
RU (1) RU2077336C1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2140285C1 (en) 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Antiviral agent - nasal drops "grippferon"
RU2488405C1 (en) * 2012-07-17 2013-07-27 Илья Александрович Марков Drug herpferon-2 possessing antiviral, anti-inflammatory, immunomodulatory and analgesic action for local and external application
EP3485899A4 (en) 2017-09-25 2020-05-20 Georgy Georgievich Chumburidze Thermostable composition with antiviral and antibacterial activity and use thereof
CN115105584B (en) * 2022-06-28 2023-03-31 长春生物制品研究所有限责任公司 Interferon injection liquid packaged by cartridge bottle multi-dose pen type injection combination

Also Published As

Publication number Publication date
RU2077336C1 (en) 1997-04-20

Similar Documents

Publication Publication Date Title
US4847079A (en) Biologically stable interferon compositions comprising thimerosal
ES2163444T3 (en) COMPOSITIONS AND METHODS FOR THE ORAL ADMINISTRATION OF PHARMACOS.
ES2526707T3 (en) Purification and stabilization of peptides and proteins in pharmaceutical agents
CN1993139B (en) Stabilized interferon liquid formulations
UA79430C2 (en) Method for the stepwise attachment of polyethylene glycol to polypeptide
JP2000510813A (en) Formulation for IL-12
JP2011225599A (en) Human serum albumin-free stabilized interferon liquid formulation
HU225494B1 (en) Stable, aqueous alfa interferon solution formulations
JP2005527470A5 (en)
US4895716A (en) Stabilized formulations of gamma interferons
JPH0558000B2 (en)
KR900015749A (en) Interleukin-1 formulation
KR100399156B1 (en) Liquid Formulation of α-Interferon
RU94042742A (en) Preparation of genetic engineering gamma-interferon
AU636653B2 (en) Stabilized leukocyte-interferons
HU224613B1 (en) Stabile aquous solution of hybrid alpha-interferon
IE64232B1 (en) Non-glycosylated recombining human il2 in reduced form the process for obtaining it and its use as a medicament
JP2818834B2 (en) IL-1α stabilized pharmaceutical preparation
CA1340269C (en) Homogeneous dimeric m-csf and storage stable formulations thereof
HU218103B (en) Pharmaceutical composition containing non-glycosylated recombinant human interleukin-2 and process for producing it
DE3605908A1 (en) Process for purifying interferon
Allen et al. Hybrid (BDBB) interferon-α: preformulation studies
KR930004326A (en) Chodromodulin-II Protein
CN1201815C (en) Stabilizer for recombinant alpha-interferon liquid
JPS60260523A (en) Lyophilized drug composition of interferon

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20041207